セッション

<司会の言葉>
To realize Precision Medicine for adjuvant chemotherapy for resected colon cancer, there is a precondition that the risk of recurrence for individual patients and the onset/degree of adverse events associated with postoperative adjuvant chemotherapy (risk/benefit assessment) must be accurately predicted. In recent years, the usefulness of the "Oncotype DX test" genomic test to predict the risk of recurrence following colon cancer resection has been reported in our country. The results of a large-scale joint international phase III study (IDEA project, three months vs. six months, N>10,500 cases) to verify an optimal administration period will be reported soon. Furthermore, based on the improvement of treatment results associated with the introduction of Complete Mesocolic Excision (CME) and a change in attitude towards lymph node dissection in Europe and the United States, the standard treatment of uniformly administering oxaliplatin to Stage III colon cancer patients (including high-risk Stage II patients) has been questioned. In this symposium, we have invited Top Opinion Leaders (TOLs) from around the world with the aim of forming a consensus among Japan, the United States and Europe, and taking the first step in Precision Medicine. We hope that this symposium will allow for genuine discussions with all in attendance in this venue on what kinds of clinical questions will need to be resolved to further realize Precision Medicine in the future.
Spoken in English

ゲノム診断に基づくがんプレシジョンメディスンの実現

[演者] 土原 一哉:1
1:国立がん研究センター先端医療開発センター

Latest advance and perspective on adjuvant chemotherapy for resected colon cancer

[演者] Jeffrey A. Meyerhardt:1
1:Dana-Farber Cancer Institute

Update on adjuvant therapy in colon cancer

[演者] Aimery de Gramont:1
1:Department of Oncology, Franco-British Institute, Levallois Perret, France

遺伝子解析ツールによる結腸癌根治術後の再発予測

[演者] 沖 英次:1
[著者] 安藤 幸滋:1, 中西 良太:1, 杉山 雅彦:1, 中島 雄一郎:1, 工藤 健介:1, 久保 信英:1, 佐伯 浩司:1, 前原 喜彦:1
1:九州大学大学院 消化器・総合外科学

わが国におけるStage II, III結腸癌に対する術後補助化学療法のバイオマーカー探索:SACURA trialとACTS-CC trialより

[演者] 植竹 宏之:1
[著者] 石川 敏昭:1, 石黒 めぐみ:2, 上野 秀樹:3, 松井 茂之:4, 室谷 健太:5, 中谷 英仁:6, 手良向 聡:7, 冨田 尚裕:8, 杉原 健一:9
1:東京医科歯科大学大学院 総合外科学分野, 2:東京医科歯科大学大学院 応用腫瘍学講座, 3:防衛医科大学校 外科学, 4:名古屋大学臨床医薬学講座 生物統計学分野, 5:愛知医科大学病院 臨床研究支援センター, 6:先端医療振興財団臨床研究情報センター 医学統計部, 7:京都府立医科大学 生物統計学, 8:兵庫医科大学医学部 下部消化管外科, 9:光仁会第一病院

結腸癌術後補助化学療法の最新知見と展望-Precision Medicine実現に向けて-

[演者] 吉野 孝之:1
1:国立がん研究センター東病院

詳細検索